World Journal of Surgical Oncology最新文献

{"title":"A novel anti-reflux esophagogastric anastomosis in totally laparoscopic proximal gastrectomy: Hao's esophagogastrostomy by fissure technique (HEFT).","authors":"Ze-Qin Wang, Wen-Liang Cui, Yan-Feng Zhu, Ming-Ye Ma, Jian Wang, Zi-Hao Wang, Ya-Ping Wang, Jun Hong, Han-Kun Hao","doi":"10.1186/s12957-025-03900-4","DOIUrl":"https://doi.org/10.1186/s12957-025-03900-4","url":null,"abstract":"<p><strong>Background: </strong>For adenocarcinoma localized at the gastroesophageal junction and the upper third of the stomach, proximal gastrectomy (PG) is a commonly used surgical method that preserves gastric function. For reconstruction after PG, an effective anti-reflux technique is crucial. This study proposes a novel fundoplication and valvuloplasty esophagogastrostomy technique, named as Hao's esophagogastrostomy by fissure technique (HEFT).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 11 consecutive cases that underwent totally laparoscopic proximal gastrectomy with HEFT at Huashan Hospital, Fudan University from September 2021 to January 2024. The demographics and clinics pathologic profiles, preoperative details, and postoperative outcomes of the patients were analyzed. And the reflux conditions were evaluated 6 months after surgery by endoscopy.</p><p><strong>Results: </strong>All 11 patients successfully underwent the totally laparoscopic surgery. The operative time was 190 (150, 240) minutes, including a reconstruction duration of 30 (25, 30) minutes. No Clavien-Dindo grade II or higher complications occurred postoperatively, and the hospital stay was 6 (5, 7) days. Endoscopic findings at 6 months postoperatively indicated 2 cases of LA grade A esophagitis. Among them, 1 patient experienced reflux symptoms after overeating, which improved after using proton pump inhibitor drugs. Notably, there were no occurrences of anastomotic stenosis.</p><p><strong>Conclusion: </strong>HEFT presents a promising approach for anti-reflux reconstruction following proximal gastrectomy (PG), simplifying the surgical technique while maintaining favorable immediate clinical outcomes. However, given that this is a retrospective study, further research with larger-scale clinical trials and long-term follow-up is essential to validate its safety, efficacy, and long-term benefits.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"263"},"PeriodicalIF":2.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of extent thyroidectomy and radioactive iodine ablation for disease free survival in the intermediate-risk patients with lateral neck lymph node metastasis: a retrospective and tentative real-world approach.","authors":"Kiyomi Horiuchi, Yuki Yamanashi, Tomoyoshi Nakai, Juro Yanagida, Yusaku Yoshida, Yoko Omi, Takahiro Okamoto","doi":"10.1186/s12957-025-03912-0","DOIUrl":"https://doi.org/10.1186/s12957-025-03912-0","url":null,"abstract":"<p><strong>Background: </strong>It is controversial whether or not total thyroidectomy followed by radioactive iodine ablation (RAI-a) (30 mCi = 1.1 GBq) is mandatory in intermediate-risk patients with lateral neck lymph node metastasis (cN1b).</p><p><strong>Methods: </strong>This retrospective observational study enrolled PTC patients classified preoperatively as the intermediate-risk with cN1b from January 2010 to December 2017 according to the guidelines for thyroid tumors of the Japanese Association of Endocrine Surgeons (JAES) since 2009. We analyzed recurrence-free survival (RFS) rates estimated by the Kaplan-Meier method in the patients classified into three groups: 1) total thyroidectomy (TTx) followed by lateral neck lymph node dissection (LLND) with RAI-a, 2) TTx + LLND without RAI-a, 3) hemithyroidectomy + LLND. In addition, propensity score analysis adjusted by clinical parameters was performed.</p><p><strong>Results: </strong>Two hundred eighty-eight patients with intermediate-risk PTC were identified. Among them, 87 patients with cN1b were analyzed. Five-year RFS rates in 1), 2), and 3) groups were 85.0%, 100%, and 90.9%, respectively. The analysis of 1) and 2) groups by propensity score matching revealed 5-yr RFS rates of 84.1% and 100%, respectively (p < 0.0432).</p><p><strong>Conclusions: </strong>There was no evidence to support the use of 30 mCi (1.1GBq) radioactive iodine postoperatively to prevent recurrence in intermediate-risk PTC patients with cN1b.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"262"},"PeriodicalIF":2.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application and advances of patient activation in surgical patients.","authors":"Yuanyuan Yin, Jie Zhang, Xingxia Long, Mei Yang, Kaidi Li, Cheng Shen","doi":"10.1186/s12957-025-03911-1","DOIUrl":"10.1186/s12957-025-03911-1","url":null,"abstract":"<p><p>Patient activation, a critical indicator of patients' engagement in their healthcare management and treatment decision-making, has gained increasing attention in surgical settings. This review delves into the current applications, effectiveness evaluations, influencing factors, and intervention strategies of patient activation among surgical patients. It aims to comprehensively analyze its role in enhancing postoperative recovery quality, reducing complications, improving quality of life, and provide theoretical foundations for clinical practice and research.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"261"},"PeriodicalIF":2.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative adjuvant transarterial chemoembolization prolongs overall survival in alpha-fetoprotein-negative hepatocellular carcinoma with bile duct tumor thrombosis: a long-term retrospective cohort study.","authors":"Xin-Wei Yang, Jun Chen, Mu-Qing Yang, Rong-Zheng Ran, Hai-Yan Gu, Hua Wang, Tian-Geng You, Biao Duan, Qing-De Wang, Feng Shen, Wei-Feng Tan","doi":"10.1186/s12957-025-03917-9","DOIUrl":"10.1186/s12957-025-03917-9","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) with bile duct tumor thrombosis (BDTT) is a rare clinical condition with rapid disease progression and poor prognosis. This study aimed to evaluate the prognostic value of postoperative adjuvant transarterial chemoembolization (PA-TACE) among HCC-BDTT patients after radical resection (R0).</p><p><strong>Methods: </strong>Between January 2002 and December 2010, 93 HCC-BDTT patients who underwent R0 resection were enrolled for a retrospective study, including 46 patients with PA-TACE and 47 patients without PA-TACE within two months postoperatively. The correlation between PA-TACE and the long-term prognosis of patients was analysed. Independent risk factors were identified by univariate and multivariate analysis.</p><p><strong>Results: </strong>Overall, PA-TACE did not significantly improve disease-free survival (DFS) or overall survival (OS) in the entire cohort (median OS: 25 vs. 16 months, P = 0.106). However, alpha fetoprotein (AFP)-negative patients receiving PA-TACE demonstrated significantly prolonged DFS (5-year: 50.8% vs. 11.6%, P = 0.030) and OS (5-year: 64.0% vs. 26.3%, P = 0.005). AFP (HR = 3.79, 95% CI 2.06-6.98, P < 0.001) and ALP (HR = 2.12, 95% CI 1.11-4.06, P = 0.023) were independent risk factors for OS. PA-TACE showed no benefit in AFP-positive patients (5-year OS: 0% vs. 9.4%, P = 0.859). Elevated ALP (≥ 130 U/L) correlated with worse DFS (5-year: 3.1% vs. 19.6%, P = 0.027) and OS (5-year: 8.8% vs. 22.3%, P = 0.020).</p><p><strong>Conclusion: </strong>Preoperative serum AFP and alkaline phosphatase were independent risk factors for evaluating the prognosis of HCC-BDTT. Postoperative prophylactic TACE can significantly prolong overall survival of HCC-BDTT in AFP-negative patients but not in AFP-positive cases, highlighting the need for tailored adjuvant therapies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"260"},"PeriodicalIF":2.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12219712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab.","authors":"Satoshi Mii, Hiroyuki Kato, Takeshi Takahara, Masayuki Kojima, Yutaro Kato, Zenichi Morise, Akihiko Horiguchi, Koichi Suda","doi":"10.1186/s12957-025-03834-x","DOIUrl":"10.1186/s12957-025-03834-x","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancer (BTC) is a type of malignancy that is challenging to manage. Further, advanced-stage BTC has poor prognosis. Based on the recent TOPAZ-1 trial, adding durvalumab to gemcitabine and cisplatin significantly improves survival in unresectable BTC, thereby making it the new standard first-line treatment. However, real-world data are essential to validate its efficacy and safety in routine clinical settings, which often involve older patients and those with comorbidities or previous therapies. This study aimed to evaluate the outcomes of combination chemotherapy with gemcitabine, cisplatin, and durvalumab (GCD) in a real-world cohort with BTC.</p><p><strong>Methods: </strong>This retrospective analysis included patients with unresectable advanced-stage BTC treated with GCD between December 2022 and April 2024 at three institutions. GCD was administered for up to eight cycles, followed by durvalumab monotherapy. Clinical data, including the characteristics of the patients, adverse events, and treatment responses, were collected. The Kaplan-Meier method and the Cox proportional hazards model were used to assess progression-free survival (PFS), overall survival (OS), and other factors affecting outcomes.</p><p><strong>Results: </strong>The current study included 54 patients with a median age of 72 years. Half of the patients had recurrence post-surgery, and many of them had previously received chemotherapy. The median PFS and OS rates were 4.1 and 8.0 months, respectively. Adverse events (AEs) were frequently observed, with 42.1% of patients presenting with grade 3 or higher AEs. However, immune-related AEs were rare and mild. Dose adjustments, which are often caused by renal impairment or fatigue, were common (66.7%). Multivariate analysis revealed that older age, a lower performance status score, and a high neutrophil-to-lymphocyte ratio (NLR) were significant predictors of a shorter PFS. Further, a lower performance status score, and a high NLR were associated with a low OS.</p><p><strong>Conclusions: </strong>GCD combination chemotherapy is a viable treatment option for advanced-stage BTC in a real-world setting where dose modifications can improve tolerability among elderly patients. Neutrophil-to-lymphocyte ratio can be a prognostic biomarker of OS in patients with BTC receiving immune checkpoint inhibitors. This finding highlights the potential of individualized treatment strategies. Nevertheless, further research should be performed to validate these results in larger cohorts.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"258"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between appendectomy and increased invasion of ascending colon cancer: a retrospective study involving 880 patients.","authors":"Xu Sun, Rui Li, Wen Zhao, Dingchang Li, Guanglong Dong","doi":"10.1186/s12957-025-03896-x","DOIUrl":"10.1186/s12957-025-03896-x","url":null,"abstract":"<p><strong>Background: </strong>Ascending colon cancer is a subtype of colorectal cancer (CRC), the most common malignant tumor globally. The appendix has been considered to be a vestigial organ and appendectomy is the most routine management of acute appendicitis. However, limited studies have examined the association between appendectomy and the invasion of ascending colon cancer.</p><p><strong>Methods: </strong>In this retrospective study, 880 cases of ascending colon cancer were selected. The preoperative and postoperative clinicopathological features were retrospectively studied. Logistic regression was performed and the propensity score matching (PSM) method was used to adjust for confounding factors.</p><p><strong>Results: </strong>In total of 880 patients, 133 patients had a history of appendectomy. Patients with a history of appendectomy exhibited a higher proportion of number of lymph node metastasis (LNM) (P = 0.047), T4 stage (P = 0.025), N1 stage (P = 0.037), N2 stage (P = 0.045), M1 stage (P = 0.008), stage III (P = 0.047), and stage IV (P = 0.003). The model following PSM revealed that a history of appendectomy was associated with an increased risk of LNM and M1. In 747 patients without a history of appendectomy, 568 patients (76.0%) were diagnosed with chronic appendicitis pathologically. Patients with chronic appendicitis had significantly smaller tumor sizes (P = 0.012), reduced lymphovascular invasion (LVI) (P = 0.001), fewer poorly differentiated tumors (P = 0.012,), a lower number of LNM (P = 0.020), less frequent T4 stage tumors (P = 0.023), and a decreased incidence of N2 stage disease (P = 0.035).</p><p><strong>Conclusions: </strong>Appendectomy is associated with a higher aggressiveness of subsequent ascending colon cancer, particularly regarding LNM. Chronic appendicitis has been linked to a decrease in tumor invasion of ascending colon cancer.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"253"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The delaying effect of toripalimab on disease progression in patients with advanced hepatocellular carcinoma and changes in serum tumor markers.","authors":"Zhuo Yin, Yaomin Xiao, Jiangxue Gu, Pei Hu, Jiandu Jing, Xia Wang, Yao Liu, Shirong Yan","doi":"10.1186/s12957-025-03884-1","DOIUrl":"10.1186/s12957-025-03884-1","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"254"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare IDH-Mutant glioma case: insights from single-cell transcriptomic analysis of tumor recurrences.","authors":"Wen Li, Yuanshuai Zhou, Shaheryar Shafi, Jun Dong, Minxuan Sun","doi":"10.1186/s12957-025-03913-z","DOIUrl":"10.1186/s12957-025-03913-z","url":null,"abstract":"<p><strong>Background: </strong>Isocitrate dehydrogenase (IDH) mutations are associated with better prognosis and longer survival in gliomas. In contrast, multifocal glioma is a rare intracranial tumor, primarily affecting middle-aged and elderly individuals. While recurrence is common due to the complex tumor microenvironment, cellular heterogeneity, and clonal evolution, multifocal recurrence originating from an initially unifocal, low-grade glioma has been rarely reported.</p><p><strong>Case presentation: </strong>We present the case of a 36-year-old male initially diagnosed with oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3. After gross total resection and standard chemoradiotherapy, the patient developed multifocal recurrence after three years, with new lesions in the left temporal and frontal lobes. Histopathological analysis revealed divergent progression: the distal temporal lesion demonstrated glioblastoma-like features, whereas the in situ frontal recurrence retained characteristics of oligodendroglioma. To investigate the mechanism of multifocal tumor recurrence, we performed single-cell sequencing analysis on both foci, revealing distinct cellular compositions and hidden lineage relationships among malignant cells.</p><p><strong>Discussion and conclusion: </strong>We describe a rare case of multifocal glioma recurrence in a middle-aged adult, highlighting the cellular heterogeneity and lineage relationships between distinct tumor foci. This case contributes to the limited literature on multifocal glioma recurrence and provides a well-characterized specimen for investigating the molecular distinctions between IDH-mutant and IDH-wildtype gliomas.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"259"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging and histopathological considerations in determining the primary site and differential diagnosis of gallbladder liposarcoma.","authors":"Jiro Ichikawa, Shinji Furuya, Tomonori Kawasaki, Kojiro Onohara, Masanori Wako, Satoshi Ochiai, Tetsuo Hagino, Hirotaka Haro","doi":"10.1186/s12957-025-03915-x","DOIUrl":"10.1186/s12957-025-03915-x","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"256"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study.","authors":"Junxiao Wang, Yushuai Yu, Qisheng Lin, Xin Wang","doi":"10.1186/s12957-025-03909-9","DOIUrl":"10.1186/s12957-025-03909-9","url":null,"abstract":"<p><strong>Background: </strong>For HER2-positive early-stage breast cancer patients who have received neoadjuvant chemotherapy with trastuzumab and pertuzumab (HP), it remains unclear whether to intensify treatment with T-DM1 or to continue with HP therapy in the presence of residual disease identified in postoperative pathology.</p><p><strong>Methods: </strong>This retrospective study included patients at two cancer centers in China from January 2020 to August 2022. Patients were subsequently treated with either continued HP or intensified therapy with T-DM1 for one year. A multivariable Cox proportional hazards regression model was used to identify factors influencing patient outcomes. Propensity score matching(PSM) was employed to mitigate the impact of confounding variables, and disease-free survival(DFS) between the T-DM1 and HP groups was compared.</p><p><strong>Results: </strong>Before PSM, 114 patients were included, with 24 in the T-DM1 group and 90 in the HP group. Multivariate analysis revealed that patients in ypStage I/II had a higher DFS than those in ypStage III. In the T-DM1 group, 14 patients (58.3%) experienced thrombocytopenia, with 12 affected during cycles 2 to 4. After PSM, no statistically significant difference in DFS between the two groups (P = 0.48). The 1, 2, and 3-year DFS rates for the T-DM1 group were 94.7%, 94.7%, and 94.7%, respectively, while for the HP group, they were 100%,100%, and 89.5%.</p><p><strong>Conclusions: </strong>In patients with HER2-positive early breast cancer who have residual disease after receiving neoadjuvant treatment with HP, the continued administration of HP can achieve therapeutic effects comparable to those of T-DM1, without significant complications.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"255"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}